CLINICAL_TRIALS
trial_result
· 2018-10-12
Clinical Trial Update: Omalizumab in Severe and Refractory Solar Urticaria [Phase 2]
Summary
Phase 2 trial evaluating omalizumab for severe and refractory solar urticaria has completed with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Solar Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2018-10-12